Expression and regulation of cytochrome P450 enzymes in primary cultures of human hepatocytes

被引:0
|
作者
LeCluyse, E
Madan, A
Hamilton, G
Carroll, K
DeHaan, R
Parkinson, A
机构
[1] Univ N Carolina, Sch Pharm, Chapel Hill, NC 27599 USA
[2] Univ Kansas, Med Ctr, Dept Pharmacol Toxicol & Therapeut, Ctr Environm & Occupat Hlth, Kansas City, KS 66160 USA
[3] XenoTech LLC, Kansas City, KS 66103 USA
关键词
enzyme induction; in vitro models; human hepatocytes; cytochrome P450;
D O I
10.1002/(SICI)1099-0461(2000)14:4<177::AID-JBT1>3.0.CO;2-4
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The aim of this study was to test suitable culture conditions for maintaining normal cellular cytoarchitecture and inducibility of P450 enzymes in primary cultures of human hepatocytes by prototypical inducers. The selectivity and sensitivity of a sandwich culture system were determined by treating cultures with a number of clinically relevant drugs that are known to be inducers of either rodent and/or human P450 enzymes. The results showed that considerable induction of CYP3A4 activity is observed at DMSO concentrations greater than 0.1% (v/v). No differences in P450 induction response were observed between cultures maintained under different matrix conditions. However, the matrix condition considered to be optimal for maintaining cellular integrity, protein yields, and P450 enzyme induction was a sandwich configuration in combination with modified Chee's medium containing insulin (6.25 mu g/mL) and dexamethasone (less than or equal to 0.1 mu M). Under these conditions, induction of CYP3A4 occurred at clinically relevant drug concentrations, and maximal activities were achieved after 3 days of exposure. Overall, the response of human hepatocyte cultures to treatment with both positive and negative modulators was found to reflect that observed in vivo with respect to both enzyme specificity and potency of enzyme induction, although considerable sample-to-sample variability was observed in the magnitude of induction. (C) 2000 John Wiley & Sons, Inc.
引用
收藏
页码:177 / 188
页数:12
相关论文
共 50 条
  • [31] Cytochrome p450 enzymes
    Donaldson, D
    JOURNAL OF THE ROYAL SOCIETY FOR THE PROMOTION OF HEALTH, 2000, 120 (03): : 150 - 151
  • [32] Ginseng Extracts Facilitate Cytochrome P450 Xenobiotic Metabolism in Primary Cultures of Rat Hepatocytes
    Kawase, Atsushi
    Takeshita, Fumiaki
    Yamada, Ayano
    Murata, Kazuya
    Matsuda, Hideaki
    Samukawa, Keiichi
    Iwaki, Masahiro
    JOURNAL OF HEALTH SCIENCE, 2009, 55 (05) : 809 - 813
  • [33] EXPRESSION OF MULTIPLE FORMS OF CYTOCHROME P450 MESSENGER-RNAS IN PRIMARY CULTURES OF RAT HEPATOCYTES MAINTAINED ON MATRIGEL
    KOCAREK, TA
    SCHUETZ, EG
    GUZELIAN, PS
    MOLECULAR PHARMACOLOGY, 1993, 43 (03) : 328 - 334
  • [34] Metabolism of Evodiamine by Human Cytochrome P450 Enzymes
    Fang, Zhong-Ze
    Yang, Ling
    DRUG METABOLISM REVIEWS, 2009, 41 : 99 - 99
  • [35] Oxidation of indole by human cytochrome P450 enzymes
    Guengerich, FP
    Cai, H
    Notley, LM
    DeVoss, JJ
    Gillam, EMJ
    FASEB JOURNAL, 2000, 14 (08): : A1436 - A1436
  • [36] Ipriflavone as an inhibitor of human cytochrome P450 enzymes
    Monostory, K
    Vereczkey, L
    Lévai, F
    Szatmári, I
    BRITISH JOURNAL OF PHARMACOLOGY, 1998, 123 (04) : 605 - 610
  • [37] INTERACTIONS OF ICLAPRIM WITH HUMAN CYTOCHROME P450 ENZYMES
    Hall, Michael
    Matthews, Anne
    Paul, Danny S.
    Foster, John R.
    Holding, Jeremy D.
    Islam, Khalid
    Brandt, Roger D.
    DRUG METABOLISM REVIEWS, 2007, 39 : 210 - 210
  • [38] Activation of procarcinogens by human cytochrome P450 enzymes
    Guengerich, FP
    Shimada, T
    MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, 1998, 400 (1-2) : 201 - 213
  • [39] Ipriflavone as an inhibitor of human cytochrome P450 enzymes
    Monostory, K
    Vereczkey, L
    FASEB JOURNAL, 1997, 11 (09): : A823 - A823
  • [40] Influence of rifampicin on the expression and function of human intestinal cytochrome P450 enzymes
    Glaeser, H
    Drescher, S
    Eichelbaum, M
    Fromm, MF
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 59 (02) : 199 - 206